A Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of SHR7280 Tablets in Healthy Subjects.
Latest Information Update: 29 Oct 2021
At a glance
- Drugs SHR 7280 (Primary)
- Indications Endometriosis; Sex hormone disorders
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 21 Oct 2021 Status changed from not yet recruiting to completed.
- 21 Sep 2020 New trial record